Who
Frank Karbe
Director
Company insider
Files Form 4 as: Director, Phathom Pharmaceuticals; Chief Financial Officer, Cidara Therapeutics; Chief Executive Officer, Better Therapeutics; Principal Fin'l & Accounting, Myovant Sciences; Director, Aduro Biotech; Director, Arbutus Biopharma; EVP and CFO, Exelixis.
In numbers
- Trades disclosed
- 140
- Buys
- 8
- Sells
- 15
- Bought
- $684K
- Sold
- $1.6M
- Companies
- 7
- Companies where not an officer
- 3
- First trade
- 8 Dec 2006
- Last trade
- 19 May 2026
- Last filed
- 21 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 May 2026filed 21 May 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,122 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,122 at $0.00 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara TherapeuticsBiotechnology | SEC FORM 4 Code D | $1.7M7,526 at $221.50 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara TherapeuticsBiotechnology | SEC FORM 4 Code D | —43,125 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —115,000 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —115,000 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeutics | SEC FORM 4 Code D | $1.7M7,526 at $221.50 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeutics | SEC FORM 4 Code D | —43,125 | filing |
| 10 Dec 2025filed 12 Dec 2025 | Cidara Therapeutics | SEC FORM 4 Code F | $1.6M7,290 at $219.60 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | Cidara Therapeutics | SEC FORM 4 Code A | —57,500 at $0.00 | filing |
| 13 Dec 2024filed 16 Dec 2024 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $99K12,500 at $7.93 | filing |
| 29 May 2024filed 31 May 2024 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $254K25,000 at $10.16 | filing |
| 23 May 2024filed 24 May 2024 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 23 May 2024filed 24 May 2024 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 18 Dec 2023filed 20 Dec 2023 | Better Therapeutics | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 27 Jul 2023filed 31 Jul 2023 | Better Therapeutics | SEC FORM 4 Bought | $100K137,005 at $0.73 | filing |
| 25 May 2023filed 30 May 2023 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
News
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026PHAT · manilatimes.net · 19 Oct 2026Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsPHAT · dailypolitical.com · 11 Oct 2026Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific MeetingPHAT · manilatimes.net · 8 Oct 2026Exelixis v. MSN Shows the Reach of Earlier Genus PatentsEXEL · natlawreview.com · 7 Oct 2026
0 headlines in the last 90 days name Frank Karbe; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.